Humanized gene replacement in mice reveals the contribution of cancer stroma-derived HB-EGF to tumor growth

Cell Structure and Function

Volumn 35, Issue 1, 2010, Pages 3-13

  Ichise, Tomoko ^a   Adachi, Satoshi ^a   Ohishi, Minako ^a   Ikawa, Masahito ^a   Okabe, Masaru ^a   Iwamoto, Ryo ^a   Mekada, Eisuke ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

CRM197; Diphtheria toxin; HB EGF; Stroma; Tumorigenesis

Indexed keywords

DIPHTHERIA TOXOID CRM197; HEPARIN BINDING EPIDERMAL GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; SURVIVAL RATE; TOXICITY TESTING; TUMOR; TUMOR GROWTH;

ANIMALS; BACTERIAL PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE KNOCK-IN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; NEOPLASMS; STROMAL CELLS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

MUS;

EID: 77950374846     PISSN: 03867196     EISSN: 13473700     Source Type: Journal    
DOI: 10.1247/csf.09025     Document Type: Article

References (26)

1. Bhowmick, N.A., Neilson, E.G., and Moses, H.L. 2004. Stromal fibroblasts in cancer initiation and progression. Nature, 432: 332-337.
2. Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., and Lavelle, F. 1991. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 51: 4845-4852.
3. Bos, P.D., Zhang, X.H., Nadal, C., Shu, W., Gomis, R.R., Nguyen, D.X., Minn, A.J., van de Vijver, M.J., Gerald, W.L., Foekens, J.A., and Massague, J. 2009. Genes that mediate breast cancer metastasis to the brain. Nature, 459: 1005-1009.
4. Folkman, J. and Shing, Y. 1992. Angiogenesis. J. Biol. Chem., 267: 10931-10934.
5. Goishi, K., Higashiyama, S., Klagsbrun, M., Nakano, N., Umata, T., Ishikawa, M., Mekada, E., and Taniguchi, N. 1995. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol. Biol. Cell, 6: 967-980.
6. Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C., and Klagsbrun, M. 1991. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science, 251: 936-939.
7. Higashiyama, S., Abraham, J.A., and Klagsbrun, M. 1993. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J. Cell Biol., 122: 933-940.
8. Iwamoto, R., Higashiyama, S., Mitamura, T., Taniguchi, N., Klagsbrun, M., and Mekada, E. 1994. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J., 13: 2322-2330.
9. Iwamoto, R., Yamazaki, S., Asakura, M., Takashima, S., Hasuwa, H., Miyado, K., Adachi, S., Kitakaze, M., Hashimoto, K., Raab, G., Nanba, D., Higashiyama, S., Hori, M., Klagsbrun, M., and Mekada, E. 2003. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. USA, 100: 3221-3226.
10. Kageyama, T., Ohishi, M., Miyamoto, S., Mizushima, H., Iwamoto, R., and Mekada, E. 2007. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J. Biochem., 142: 95-104.
11. Kalluri, R. and Zeisberg, M. 2006. Fibroblasts in cancer. Nat. Rev. Cancer, 6: 392-401.
12. Mitamura, T., Higashiyama, S., Taniguchi, N., Klagsbrun, M., and Mekada, E. 1995. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/ diphtheria toxin receptor and inhibits specifically its mitogenic activity. J. Biol. Chem., 270: 1015-1019.
13. Mitamura, T., Umata, T., Nakano, F., Shishido, Y., Toyoda, T., Itai, A., Kimura, H., and Mekada, E. 1997. Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenesis. J. Biol. Chem., 272: 27084-27090.
14. Miyamoto, S., Hirata, M., Yamazaki, A., Kageyama, T., Hasuwa, H., Mizushima, H., Tanaka, Y., Yagi, H., Sonoda, K., Kai, M., Kanoh, H., Nakano, H., and Mekada, E. 2004. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res., 64: 5720-5727.
15. Miyamoto, S., Yagi, H., Yotsumoto, F., Kawarabayashi, T., and Mekada, E. 2006. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci., 97: 341-347.
16. Mueller, M.M. and Fusenig, N.E. 2004. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer, 4: 839-849.
17. Normanno, N., Bianco, C., De Luca, A., Maiello, M.R., and Salomon, D.S. 2003. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer, 10: 1-21.
18. Ongusaha, P.P., Kwak, J.C., Zwible, A.J., Macip, S., Higashiyama, S., Taniguchi, N., Fang, L., and Lee, S.W. 2004. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res., 64: 5283-5290.
19. Raab, G. and Klagsbrun, M. 1997. Heparin-binding EGF-like growth factor. Biochim. Biophys. Acta, 1333: F179-199.
20. Sakai, K. and Miyazaki, J. 1997. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. Biochem. Biophys. Res. Commun., 237: 318-324.
21. Takazaki, R., Shishido, Y., Iwamoto, R., and Mekada, E. 2004. Suppres-sion of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like growth factor. J. Biol. Chem., 279: 47335-47343.
22. Tlsty, T.D. and Coussens, L.M. 2006. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol., 1: 119-150.
23. Uchida, T., Pappenheimer, A.M.J., and Greany, R. 1973. Diphtheria toxin and related proteins. I. Isolation and some properties of mutant proteins serologically related to diphtheria toxin. J. Biol. Chem., 248: 3838-3844.
24. Umata, T., Moriyama, Y., Futai, M., and Mekada, E. 1990. The cytotoxic action of diphtheria toxin and its degradation in intact Vero cells are inhibited by bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase. J. Biol. Chem., 265: 21940-21945.
25. Yamazaki, S., Iwamoto, R., Saeki, K., Asakura, M., Takashima, S., Yamazaki, A., Kimura, R., Mizushima, H., Moribe, H., Higashiyama, S., Endoh, M., Kaneda, Y., Takagi, S., Itami, S., Takeda, N., Yamada, G., and Mekada, E. 2003. Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J. Cell Biol., 163: 469-475.
26. Yotsumoto, F., Yagi, H., Suzuki, S.O., Oki, E., Tsujioka, H., Hachisuga, T., Sonoda, K., Kawarabayashi, T., Mekada, E., and Miyamoto, S. 2008. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem. Biophys. Res. Commun., 365: 555-561.